It is therefore anticipated that anatabine has the potential to mitigate the three main pathologies associated with AD: tau hyperphosphorylation, Aß accumulation and neuroinflammation.
What would big pharma be willing to pay for something that could really benefit AD patients?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.